Incyte Stock Alpha and Beta Analysis
| INCY Stock | USD 73.52 1.80 2.51% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Incyte. It also helps investors analyze the systematic and unsystematic risks associated with investing in Incyte over a specified time horizon. Remember, high Incyte's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Incyte's market risk premium analysis include:
Beta 1.08 | Alpha 0.0985 | Risk 2.51 | Sharpe Ratio 0.0839 | Expected Return 0.21 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Incyte |
Incyte Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Incyte market risk premium is the additional return an investor will receive from holding Incyte long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Incyte. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Incyte's performance over market.| α | 0.1 | β | 1.08 |
Incyte expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Incyte's Buy-and-hold return. Our buy-and-hold chart shows how Incyte performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Incyte Market Price Analysis
Market price analysis indicators help investors to evaluate how Incyte stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Incyte shares will generate the highest return on investment. By understating and applying Incyte stock market price indicators, traders can identify Incyte position entry and exit signals to maximize returns.
Incyte Return and Market Media
The median price of Incyte for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 66.12 with a coefficient of variation of 8.34. The daily time series for the period is distributed with a sample standard deviation of 5.73, arithmetic mean of 68.65, and mean deviation of 4.7. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 382 shares by Thomas Tray of Incyte at 63.37 subject to Rule 16b-3 | 09/13/2024 |
2 | Disposition of 2136 shares by Sheila Denton of Incyte at 67.63 subject to Rule 16b-3 | 10/11/2024 |
3 | Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable Growth During the Study Period DelveInsight | 10/23/2024 |
4 | Incytes Jakafi Demand Is Strong, Analyst Upgrades Stock | 10/30/2024 |
5 | Disposition of 2256 shares by Flannelly Barry P of Incyte at 68.62 subject to Rule 16b-3 | 11/06/2024 |
6 | Acquisition by Flannelly Barry P of 2256 shares of Incyte at 68.62 subject to Rule 16b-3 | 11/08/2024 |
7 | ARMISTICE CAPITAL, LLC Acquires Significant Stake in Eyenovia Inc | 11/15/2024 |
8 | Is Incyt Corporation the Best Immunotherapy Stock to Buy Now | 11/18/2024 |
9 | ASX set to slip, global markets fall on rising Russia-Ukraine tensions | 11/19/2024 |
10 | Hidradenitis Suppurativa Market to Showcase Remarkable Growth at a CAGR of 12.4 percent by 2034 DelveInsight | 11/20/2024 |
11 | Biotech Stock Roundup SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval More | 11/21/2024 |
12 | Goldman Sachs Incyte Corporation Is A Top Growth Investor Stock | 11/22/2024 |
13 | Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting | 11/25/2024 |
About Incyte Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Incyte or other stocks. Alpha measures the amount that position in Incyte has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.88 | 0.75 | 2.33 | 2.44 | Days Of Inventory On Hand | 137.64 | 213.29 | 90.14 | 150.23 |
Incyte Upcoming Company Events
As portrayed in its financial statements, the presentation of Incyte's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Incyte's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Incyte's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Incyte. Please utilize our Beneish M Score to check the likelihood of Incyte's management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Incyte
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.